Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14272905 | 0.88 | OPRM1 (0.76) | OPRM1KMT2ASLC6A4SLC6A3OPRL1 | |
| SCHEMBL4826627 | 0.85 | OPRM1 (0.71) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL5166604 | 0.82 | OPRM1 (0.97) | OPRM1KMT2A | |
| SCHEMBL1611 | 0.82 | OPRM1 (0.67) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL7377089 | 0.82 | OPRM1 (0.67) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL4657423 | 0.81 | OPRM1 (0.67) | OPRM1KMT2ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16691415 | 0.81 | OPRM1 (0.66) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL626042 | 0.80 | OPRM1 (0.65) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL31441136 | 0.80 | OPRM1 (0.65) | OPRM1SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL5758344 | 0.80 | KMT2A (0.66) | OPRM1KMT2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549615-B1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1581495-B1 | 4-aryl-4-(naphth-1-ylmethylamino)methyl-piperidine compounds and their use | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-20060241142-A1 | Naphthamide derivatives and their use | ALEATEL WIRELESS, INC. | 2006-10-26 | — | — | US | disclosed |
| US-20060058352-A1 | Piperidine amine compounds and their use | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20050245572-A1 | Naphthyl ether compounds and their use | OLINK AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1581495-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1549615-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1546101-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004056771-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004022539-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004020411-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058352-A1 | Piperidine amine compounds and their use | HRH3, H1-5, H1-0 | OPRM1 161/4885KMT2A 245/4885SLC6A4 752/4885 |
| US-20050245572-A1 | Naphthyl ether compounds and their use | NR4A1, NPM1, H1-4 | OPRM1 743/4885KMT2A 1575/4885SLC6A4 3111/4885 |
| US-20060241142-A1 | Naphthamide derivatives and their use | NPM1, H1-4, H1-3 | OPRM1 696/4885KMT2A 979/4885SLC6A4 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.